-
Roth Capital Reiterates Buy on Zosano Pharma (ZSAN) Following Positive ZP-Glucagon Data
-
Roth Capital Cuts Price Target on Zosano Pharma (ZSAN) Following Announced Discontinuance of ZP-PTH Agreement
-
Roth Capital Starts Zosano Pharma (ZSAN) at Buy
-
Zosano Pharma (ZSAN) IPO Opens Higher
-
Zosano Pharma (ZSAN) Prices 4.5M Common IPO at $11/Share
-
Zosano Pharma Announces Pricing of Initial Public Offering